Document is current
Any future updates will be listed below
-
Authors
Sharma, Govinda https://orcid.org/0000-0002-5675-2637
Round, James
Teng, Fei
Ali, Zahra
May, Chris
Yung, Eric
Holt, Robert A. https://orcid.org/0000-0002-7259-1247
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R21CA226321-01, 1R21CA226321-01)
Michael Smith Foundation for Health Research (I2C2020, I2C2021, I2C2021, I2C2021)
Genome British Columbia (PIF005, PIF005, PIF005, PIF005)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
BioCanRx
- License Information
-
More Information
Article History
Received: 2 January 2024
Accepted: 30 July 2024
First Online: 19 August 2024
Competing interests
: G.S. and R.A.H. are named inventors on United States Issued Patent No. 10627411 and Canada Issued Patent No. 2943569, “T cell epitope identification”. G.S., J.R., C.M., and R.A.H. are named inventors on United States Provisional Patent Application No. 63/538232, “Methods And Compositions For Performing Granzyme-Based T cell Antigen Profiling In A Fully Recombinant System”. Rights to claims from patents and patent applications mentioned here have been licensed to Immfinity Biotechnologies, Inc., in which G.S., J.R., and F.T. have financial interests.
: The study protocol was approved by the BC Cancer Research Ethics Board (REB) in accordance with the guidelines set out in the Declaration of Helsinki. All human primary tissue samples used in this study were obtained from Stemcell Technologies and were derived from leukopaks collected in the U.S. from donors providing written informed consent and under the approval of Hummingbird IRB (Cambridge, MA). Use of commercially obtained human materials at the British Columbia Cancer Research Institute was done under the oversight of the BC Cancer REB.
